PubRank

J R Mascola

Author PubWeight™ 58.17‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000 5.74
2 Detection of diverse HIV-1 genetic subtypes in the USA. Lancet 1995 3.41
3 The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997 3.36
4 Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol 1999 2.68
5 Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006 2.57
6 The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001 2.43
7 Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol 1997 1.72
8 Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol 1998 1.69
9 A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010 1.66
10 Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis 1995 1.58
11 Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol 1996 1.57
12 Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. AIDS 2000 1.53
13 Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol 1998 1.51
14 Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999 1.48
15 Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection--evidence for highly susceptible human hosts. J Infect Dis 1997 1.44
16 Red man syndrome: incidence, etiology, and prophylaxis. J Infect Dis 1991 1.43
17 Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J Virol 1999 1.38
18 Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J Virol 1998 1.27
19 HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 1998 1.22
20 Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J Virol 2000 1.22
21 Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. J Virol 1997 1.14
22 Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa. J Virol 1996 1.14
23 A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. AIDS Res Hum Retroviruses 1998 1.06
24 Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012 1.05
25 Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis 1998 1.04
26 Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res Hum Retroviruses 2001 1.03
27 Multiple introductions of HIV-1 subtype E into the western hemisphere. Lancet 1995 1.01
28 Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc Natl Acad Sci U S A 1999 0.96
29 Genetic, antigenic and serologic characterization of human immunodeficiency virus type 1 from Indonesia. J Acquir Immune Defic Syndr Hum Retrovirol 1997 0.96
30 Antigen detection in neutralization assays: high levels of interfering anti-p24 antibodies in some plasma. AIDS Res Hum Retroviruses 1993 0.94
31 Construction and biological characterization of infectious molecular clones of HIV-1 subtypes B and E (CRF01_AE) generated by the polymerase chain reaction. Virology 2000 0.93
32 A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine 2000 0.91
33 Disseminated gonococcal infection. Am Fam Physician 1992 0.90
34 Herpes simplex virus vaccines--why don't antibodies protect? JAMA 1999 0.85
35 AIDS vaccines. Are we ready for human efficacy trials? JAMA 1994 0.79
36 Transmission of HIV-1 subtype E in the united states. JAMA 1996 0.79
37 Macaque dendritic cells infected with SIV-recombinant canarypox ex vivo induce SIV-specific immune responses in vivo. AIDS Res Hum Retroviruses 2004 0.78
38 Vaccine reactions. Nat Med 1998 0.75
39 Human immunodeficiency virus type 1 candidate vaccine breakthrough infection. J Infect Dis 1995 0.75
40 Determination of HIV-1 Chemokine Coreceptor Tropism Using Transduced Human Osteosarcoma (HOS) Cells. Methods Mol Med 1999 0.75
41 Determination of Syncytium-Inducing Phenotype of Primary HIV-1 Isolates Using MT-2 cells. Methods Mol Med 1999 0.75